Blood Reviews
Volume 24, Issue 1 , Pages 27-37, January 2010

Autologous blood cell therapies from pluripotent stem cells

  • Claudia Lengerke

      Affiliations

    • Division of Hematology and Oncology, University of Tuebingen Medical Center II, 72076 Tuebingen, Germany
    • Corresponding Author InformationCorresponding author. Address: Division of Hematology and Oncology, University of Tuebingen Medical Center II, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany. Tel.: +49 7071 2982912; fax: +49 7071 294524.
    • ,
  • George Q. Daley

      Affiliations

    • Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Children’s Hospital, Boston, MA 02115, USA
    • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
    • Manton Center for Orphan Disease Research, Boston, MA 02115, USA
    • Harvard Stem Cell Institute, Cambridge, MA 02138, USA
    • Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
    • Address: Division of Hematology/Oncology, Children’s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. Tel.: +1 617 919 2015; fax: +1 617 730 0222.

published online 12 November 2009.

Summary 

The discovery of human embryonic stem cells (hESCs) raised promises for a universal resource for cell based therapies in regenerative medicine. Recently, fast-paced progress has been made towards the generation of pluripotent stem cells (PSCs) amenable for clinical applications, culminating in reprogramming of adult somatic cells to autologous PSCs that can be indefinitely expanded in vitro. However, besides the efficient generation of bona fide, clinically safe PSCs (e.g., without the use of oncoproteins and gene transfer based on viruses inserting randomly into the genome), a major challenge in the field remains how to efficiently differentiate PSCs to specific lineages and how to select cells that will function normally upon transplantation in adults. In this review, we analyse the in vitro differentiation potential of PSCs to the hematopoietic lineage by discussing blood cell types that can be currently obtained, limitations in derivation of adult-type HSCs and prospects for clinical application of PSCs-derived blood cells.

Keywords: Human embryonic stem cells, ESC, Induced pluripotent stem cells, iPS, Differentiation, Hematopoietic stem cells, Blood, Transplantation, Autologous, Isogenic, Erythrocytes, NK cells, Neutrophils, Lymphocytes

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0268-960X(09)00063-0

doi:10.1016/j.blre.2009.10.001

Blood Reviews
Volume 24, Issue 1 , Pages 27-37, January 2010

Article Tools

* Image Usage & Resolution